The triad of congenital systemic-to-pulmonary communication, cyanosis, and pulmonary arterial disease is called Eisenmenger syndrome. Eisenmenger syndrome is caused due to a birth defect. The disease is characterized by high blood pressure and abnormal blood flow through the heart. The specific symptoms of Eisenmenger syndrome vary greatly from person to person. The most notable symptom is called cyanosis, which is the bluish discoloration of the skin and mucous membranes. Eisenmenger syndrome is caused by a defect in the structure of the heart, more specifically a ventricular septal defect (VSD) or other shunt. Eisenmenger syndrome belongs to a group of conditions called pulmonary arterial hypertension-PAH.
This report contains market size and forecasts of Eisenmenger Syndrome Treatment in Global, including the following market information:
Global Eisenmenger Syndrome Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Eisenmenger Syndrome Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Antiarrhythmic Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Eisenmenger Syndrome Treatment include Actelion Pharmaceuticals Ltd., Gilead Sciences, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc., Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc. and Mylan N.V. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Eisenmenger Syndrome Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Eisenmenger Syndrome Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Eisenmenger Syndrome Treatment Market Segment Percentages, by Type, 2021 (%)
Antiarrhythmic Agents
Blood Thinning Agents
Endothelin Receptor Antagonist
Others
Global Eisenmenger Syndrome Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Eisenmenger Syndrome Treatment Market Segment Percentages, by Application, 2021 (%)
Blood tests
Electrocardiogram (ECG)
Chest X-ray
Echocardiogram
Computerized tomography (CT) scan
Magnetic resonance imaging (MRI)
Cardiac catheterization
Walking test
Global Eisenmenger Syndrome Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Eisenmenger Syndrome Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Eisenmenger Syndrome Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Eisenmenger Syndrome Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Actelion Pharmaceuticals Ltd.
Gilead Sciences, Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
AstraZeneca plc.
Novartis AG
Merck & Co., Inc.
GlaxoSmithKline plc.
Mylan N.V.
Bayer AG